2023 CPDD Peer Reviewer List.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 319, doi. 10.1002/cpdd.1387
- Publication type:
- Article
Works matching IS 2160763X AND DT 2024 AND VI 13 AND IP 3
Results: 14
1
2
Comment on: Can Intranasal Nalmefene Reduce the Number of Opioid Overdose Deaths?
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 317, doi. 10.1002/cpdd.1382
- By:
- Publication type:
- Article
3
Can Intranasal Nalmefene Reduce the Number of Opioid Overdose Deaths?
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 315, doi. 10.1002/cpdd.1381
- By:
- Publication type:
- Article
4
Bioequivalence and Safety Assessment of 2 Formulations of Low‐Dose Metformin Hydrochloride under Fasting Conditions in Healthy Chinese Participants: A Randomized Phase 1 Clinical Trial.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 307, doi. 10.1002/cpdd.1369
- By:
- Publication type:
- Article
5
No Influence of Asundexian on Cardiac Repolarization.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 265, doi. 10.1002/cpdd.1366
- By:
- Publication type:
- Article
6
Intravenous Ganaxolone: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Healthy Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 248, doi. 10.1002/cpdd.1365
- By:
- Publication type:
- Article
7
Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 297, doi. 10.1002/cpdd.1364
- By:
- Publication type:
- Article
8
Evaluation of Acarbose Bioequivalence in Healthy Chinese Populations Using Novel Pharmacodynamic End Points.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 233, doi. 10.1002/cpdd.1362
- By:
- Publication type:
- Article
9
Clinical Study on the Eradication of Helicobacter pylori by Vonoprazan Combined with Amoxicillin for 10‐Day Dual Therapy.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 240, doi. 10.1002/cpdd.1357
- By:
- Publication type:
- Article
10
Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 288, doi. 10.1002/cpdd.1356
- By:
- Publication type:
- Article
11
A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady State.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 224, doi. 10.1002/cpdd.1355
- By:
- Publication type:
- Article
12
Pharmacokinetics and Bioequivalence of Amlodipine Besylate Tablet in Healthy Chinese Volunteers Under Fasting and Fed Conditions.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 259, doi. 10.1002/cpdd.1345
- By:
- Publication type:
- Article
13
Bioequivalence Study of Capsules versus Film Tablets Containing Rivaroxaban in Healthy Caucasian Subjects under Fasting and Fed Conditions.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 281, doi. 10.1002/cpdd.1342
- By:
- Publication type:
- Article
14
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 3, p. 219, doi. 10.1002/cpdd.1116
- Publication type:
- Article